- Home
- Products
- Customized ADCs
- IL2RA
- Anti-IL2RA (Basiliximab)-MC-Vc-PAB-MMAE ADC
Anti-IL2RA (Basiliximab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-1367)
This ADC product is comprised of an anti-IL2RA monoclonal antibody conjugated via a MC-Vc linker to MMAE. The MMAE is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, MMAE binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death.
- ADC Target
- ADC Antibody
- ADC Linker
- ADC payload drug
- Name
- IL2RA
- Alternative Names
- IL2RA; interleukin 2 receptor, alpha; IL2R; interleukin-2 receptor subunit alpha; CD25; p55; IL2-RA; IL-2-RA; TAC antigen; IL-2R subunit alpha; IL-2 receptor subunit alpha; TCGFR; IDDM10;
- Target Entrez Gene ID
- 3559
- Target UniProt ID
- P01589
- Overview
- The interleukin 2 (IL2) receptor alpha (IL2RA) and beta (IL2RB) chains, together with the common gamma chain (IL2RG), constitute the high-affinity IL2 receptor. Homodimeric alpha chains (IL2RA) result in low-affinity receptor, while homodimeric beta (IL2RB) chains produce a medium-affinity receptor. Normally an integral-membrane protein, soluble IL2RA has been isolated and determined to result from extracellular proteolyisis. Alternately-spliced IL2RA mRNAs have been isolated, but the significance of each is presently unknown. Mutations in this gene are associated with interleukin 2 receptor alpha deficiency
- Overview
- Chimeric Anti-IL2RA IgG1-kappa antibody, Basiliximab
- Generic name
- Basiliximab
- Host animal
- Mouse
- Name
- MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl)
- Description
- Peptide linkers, belonging to Enzymatically cleavable linkers, combine greater systemic stability with rapid enzymatic release of the drug in the target cell. The scission of peptidic bonds relies on lysosomal proteolytic enzymes, which have very low activities in blood due to endogenous inhibitors and the unfavorably high pH value of blood.
- Name
- MMAE
- Description
- Derived from Auristatin,are water-soluble dolastatin analogs of dolastatin 10. Dolastatin 10 belongs to dolastatin family and it can powerfully bind to tubulin, thus inhibiting polymerization mediated through the binding to the vinca alkaloid binding domain, and causes cell to accumulate in metaphase arrest.
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Anti-Rabies Virus Glycoprotein (Foravirumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-1969)
- Anti-Rabies Virus Glycoprotein (Foravirumab)-MC-MMAF ADC (CAT#: ADC-W-1966)
- Anti-FLT1 (Icrucumab)-SPDB-DM4 ADC (CAT#: ADC-W-1149)
- Anti-integrin alpha(v)beta(3) (Etaracizumab)-MC-Vc-PAB-SN38 ADC (CAT#: ADC-W-1500)
- Anti-IGF1R (Dalotuzumab)-MC-Vc-PAB-SN38 ADC (CAT#: ADC-W-1266)
- Anti-ITGAL (Odulimomab)-SMCC-DM1 ADC (CAT#: ADC-W-1484)
- Anti-EGFR (Futuximab)-MC-Vc-PAB-SN38 ADC (CAT#: ADC-W-1050)
- Anti-APP (Solanezumab)-SPDB-DM4 ADC (CAT#: ADC-W-699)
- Anti-ERBB2 (Trastuzumab)-thioether SMCC-DM1 ADC (CAT#: ADC-W-414)
- Anti-CD70 (clone h1F6 C4v2)-Mc-MMAF ADC (CAT#: ADC-W-236)
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for ADC-W-1367. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Target
Same Linker
Same Payload
| CAT# | Product Name | Linker | Payload |
| ADC-W-1369 | Anti-IL2RA (Basiliximab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
| ADC-W-1372 | Anti-IL2RA (Daclizumab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-1363 | Anti-IL2RA (Inolimomab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
| ADC-W-1360 | Anti-IL2RA (Inolimomab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-1374 | Anti-IL2RA (Daclizumab)-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
| CAT# | Product Name | Linker | Payload |
| ADC-W-2593 | Anti-EGFR (Cetuximab)-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
| ADC-W-2623 | Anti-NCAM1 (Lorvotuzumab )-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
| ADC-W-2624 | Anti-NCAM1 (Lorvotuzumab )-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
| ADC-W-2613 | Anti-MS4A1 (Rituximab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
| ADC-W-2607 | Anti-ITGB3 (Tadocizumab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
| CAT# | Product Name | Linker | Payload |
| ADC-W-2601 | Anti-GPNMB (Glembatumumab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
| ADC-W-2540 | Anti-CD33 (Gemtuzumab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
| ADC-W-2623 | Anti-NCAM1 (Lorvotuzumab )-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
| ADC-W-2592 | Anti-EGFR (Cetuximab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
| ADC-W-2580 | Anti-CEACAM5-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.
